- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Douglas Wallace, Ph.D., Wins 2017 Dr. Paul Janssen Award for Biomedical Research
Johnson & Johnson Launches Campaign for Champions of Science
DARZALEX® (daratumumab) Approved by the U.S. FDA in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Who Have Received At Least Two Prior Therapies
DARZALEX combination therapy offers new option for patients previously treated with two commonly used treatments (lenalidomide and a proteasome inhibitor)
New Phase 3 Data Show Anti-TNF Alpha SIMPONI ARIA® (golimumab) Significantly Improved Arthritis And Skin Manifestations In Patients With Active Psoriatic Arthritis
Treatment with SIMPONI ARIA® Showed Significant Inhibition in the Progression of Structural Damage
INVOKANA® (canagliflozin) Significantly Reduces the Combined Risk of Cardiovascular Death, Myocardial Infarction and Stroke in the CANVAS Program
Study results published in the New England Journal of Medicine and featured in a special symposium at the American Diabetes Association 77th Scientific Sessions
Janssen and Johnson & Johnson Innovation Launch Next-Gen Baby Box QuickFire Challenge in Collaboration with Sitra, Tekes and VTT
Challenge seeks ideas and solutions to celebrate 80th anniversary of Finnish Baby Box and spur innovation to promote child health and healthy parenting
Janssen Announces Submissions in Europe and US for Single- Tablet Regimen of Dolutegravir plus Rilpivirine - the First Two-Drug HIV Maintenance Treatment
- Two-drug regimen could offer many patients the option to switch to a regimen that does not include a nucleotide reverse transcriptase inhibitor -